• Reviewer Acknowledgments

    Nov 1, 2009, 00:00

  • Growing Application of Pharmacoeconomics and Outcomes Research in Health-Care Decision-Making in the Asia-Pacific Region

    Nov 1, 2009, 00:00

  • Evidence-Based Decision-Making on Medical Technologies in China, Japan, and Singapore

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The International Society for Pharmacoecon ...

    Nov 1, 2009, 00:00

  • Psychometric Evaluation of the Diabetes Symptom Checklist-Revised (DSC-R)—A Measure of Symptom Distress

    Nov 1, 2009, 00:00

  • An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

    Nov 1, 2009, 00:00

  • A Concept Taxonomy and an Instrument Hierarchy- Tools for Establishing and Evaluating the Conceptual Framework of a Patient-Reported Outcome (PRO) Instrument as Applied to Product Labeling Claims

    Nov 1, 2009, 00:00

  • Good Research Practices for Comparative Effectiveness Research- Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources- The ISPOR Good Research Practices for Retrospective Database Analy ...

    Nov 1, 2009, 00:00

  • Costs and Health Utilities Associated with Extremely Preterm Birth- Evidence from the EPICure Study

    Nov 1, 2009, 00:00

  • Impact of Diabetes Mellitus (DM) on the Health-Care Utilization and Clinical Outcomes of Patients with Stroke in Singapore

    Nov 1, 2009, 00:00

  • The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III

    Nov 1, 2009, 00:00

  • Establishing Optimal Requirements for Content Validity- A Work in Progress

    Nov 1, 2009, 00:00

  • Economic Impact on Health-Care Costs Related to Major Diseases Including HIV/AIDS due to Alcohol Drinking among Thai Populations

    Nov 1, 2009, 00:00

  • Too Much Ado about Instrumental Variable Approach- Is the Cure Worse than the Disease?

    Nov 1, 2009, 00:00

  • Psychometric Properties of a German Version of the “Satisfaction with Information about Medicines Scale” (SIMS-D)

    Nov 1, 2009, 00:00

  • Mapping the Cancer-Specific EORTC QLQ-C30 to the Preference-Based EQ-5D, SF-6D, and 15D Instruments

    Nov 1, 2009, 00:00

  • Evaluating Minimal Important Differences for the FACT-Melanoma Quality of Life Questionnaire

    Nov 1, 2009, 00:00

  • Evaluation of Cost-Utility of Varenicline Compared with Existing Smoking Cessation Therapies in South Korea

    Nov 1, 2009, 00:00

  • PIN16 EVALUACI, D.C

    Oct 1, 2009, 00:00

  • PCN22 COMPARING THE SURVIVAL BENEFIT OF LETROZOLE AND ANASTROZOLE- A NUMBER NEEDED TO TREAT ANALYSIS

    Oct 1, 2009, 00:00

  • PSY10 TREATING FIBROMYALGIA WITH DULOXETINE- WHAT IS THE ASSOCIATION BETWEEN AVERAGE DAILY DOSE, MEDICATION ADHERENCE, AND HEALTH CARE COSTS?

    Oct 1, 2009, 00:00

  • PCV111 A PATIENTS VIEW OF THE COST-EFFECTIVENESS OF USING LOWDOSE ASPIRIN FOR CVD (CARDIOVASCULAR DISEASE) PRIMARY PREVENTION IN MIDDLE-AGED MEN IN THE UK

    Oct 1, 2009, 00:00

  • CN2 ECONOMIC EVALUATION OF THE CHEK2 GENOTYPING AND PERSONALIZED BREAST CANCER SCREENING IN THE POLISH HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PMC75 ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR SCIENTIFIC RESEARCH INITIATIVES?

    Oct 1, 2009, 00:00

  • PMC39 USING MIXED TREATMENT COMPARISON MODELING TO COMPARE PROPORTIONS OF NAIVE HBEAG(+) CHB PATIENTS WHO ACHIEVED UNDETECTABLE HBV DNA

    Oct 1, 2009, 00:00

  • PHP90 PATIENT-HEALTH CARE PROVIDER COMMUNICATION- IMPACT ON PATIENT SATISFACTION ON THE QUALITY OF HEALTH SERVICE

    Oct 1, 2009, 00:00

  • PMH50 CLINICAL VALIDITY OF REMISSION IN PATIENTS WITH MAJOR DEPRESSION IN POPULATION DATABASES

    Oct 1, 2009, 00:00

  • PG117 CONSUMPTION OF HEALTH CARE RESOURCES ASSOCIATED WITH CURRENT MANAGEMENT STRATEGIES FOR NON-VARICEAL UPPER GASTROINTESTINAL BLEEDING- AN OBSERVATIONAL EUROPEAN STUDY

    Oct 1, 2009, 00:00

  • PHP77 NEW DRUGS EVALUATION IN SPAIN- THE JOINT COMMITTEE OF NEW DRUGS EVALUATION EXPERIENCE

    Oct 1, 2009, 00:00

  • PMS27 DIRECT AND INDIRECT COSTS OF RHEUMATOID ARTHRITIS MANAGEMENT IN POLAND

    Oct 1, 2009, 00:00

  • PMC16 QUALITY ASSESSMENT OF PUBLISHED HEALTH ECONOMIC ANALYSES FROM CHINA

    Oct 1, 2009, 00:00

  • PMC20 IMPLEMENTING A BENCHMARKING MODEL FOR EXPENDITURES OF PRESCRIPTION DRUGS IN AUSTRIA

    Oct 1, 2009, 00:00

  • PDB64 A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN

    Oct 1, 2009, 00:00

  • PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND

    Oct 1, 2009, 00:00

  • PMS38 ECONOMIC ANALYSIS OF DABIGATRAN ETEXILATE FOR THE PRIMARY PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP OR KNEE REPLACEMENT IN SPAIN

    Oct 1, 2009, 00:00

  • PMS1 RISK ASSESSMENT OF CARDIOVASCULAR THROMBOTIC EVENTS, OTHER CARDIAC EVENTS, AND MORTALITY AMONG VETERANS AFFAIRS PATIENTS WITH DIFFICULT TO MANAGE GOUT

    Oct 1, 2009, 00:00

  • PCV132 DIFFERENCES IN PERSISTENCE BETWEEN CCBS WHEN COMBINED WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PP1 A SYSTEMATIC REVIEW OF THE ANALYTIC HIERARCHY PROCESS IN HEALTH CARE DECISION MAKING

    Oct 1, 2009, 00:00

  • PCV75 PATIENTS WITH PULMONARY EMBOLISM AFTER ORTHOPAEDIC SURGERY HAVE SIGNIFICANTLY INCREASED COSTS FOR INPATIENT STAY

    Oct 1, 2009, 00:00

  • PHP81 USE OF SELF-REPORTED HEALTH STATUS TO PREDICT EMPLOYEE MEDICAL EXPENDITURES

    Oct 1, 2009, 00:00

  • CS19 AUDITORIA BASEADA EM EVIDO

    Oct 1, 2009, 00:00

  • PMC15 A STANDARD COST TOOLKIT FOR ECONOMIC EVALUATIONS OF CANCER CARE IN FRANCE

    Oct 1, 2009, 00:00

  • PR1 LITERATURE REVIEW AND PRODUCT LABEL CLAIM REVIEW OF PRO MEASURES FOR BENIGN PROSTATIC HYPERPLASIA

    Oct 1, 2009, 00:00

  • PCN9 ANLISIS DE COSTOS DEL TRATAMIENTO EN PACIENTES CON SARCOMA DE TEJIDOS BLANDOS EN ETAPA TEMPRANA EN EL INSTITUTO MEXICANO DEL SEGURO SOCIAL (IMSS)

    Oct 1, 2009, 00:00

  • PIN23 POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/ RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS

    Oct 1, 2009, 00:00

  • PCN136 COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) USE AMONG LOCAL STAGE PROSTATE CANCER PATIENTS- TYPES, FACTORS ASSOCIATED WITH USE AND PERCEIVED BENEFITS

    Oct 1, 2009, 00:00

  • PRS3 A COMPARISON OF EFFICACY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1-1 DOSE RATIO IN THE TREATMENT OF BRONCHIAL ASTHMA

    Oct 1, 2009, 00:00

  • PMS58 COST-UTILITY ANALYSIS OF DIFFERENT TREATMENT STRATEGIES AFTER THE FAILURE OF FIRST BIOLOGIC TREATMENT IN RHEUMATOID ARTHRITIS (RA) IN THE FINNISH SETTING

    Oct 1, 2009, 00:00

  • PCN3 HEAD AND NECK CANCER PATIENTS AT INCREASED RISK OF COMORBIDITY COMPARED TO CANCER-FREE CONTROLS

    Oct 1, 2009, 00:00

  • PMC58 EVALUATING THE INFLUENCE OF PHYSICAL ACTIVITY ON THE SOCIAL AND ENVIRONMENTAL DOMAINS OF QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PRS18 COST-EFFECTIVENESS ANALYSIS OF FORMOTEROL ASSOCIATED TO BUDESONIDE FOR MAINTENANCE AND RELIEVER THERAPY (SYMBICORT SMART) VERSUS SALMETEROL ASSOCIATED TO FLUTICASONE IN THE TREATMENT OF MODERATE TO SEVERE PERSISTENT ASTHMA UNDER THE B ...

    Oct 1, 2009, 00:00

  • PCN28 PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME

    Oct 1, 2009, 00:00

  • PDB5 ESTIMACIRDIDA DE PRODUCTIVIDAD POR MORTALIDAD ATRIBUIBLE A LA DIABETES EN ARGENTINA

    Oct 1, 2009, 00:00

  • PCV24 A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CLINICAL TRIALS REVIEWING ANTI-ARRHYTHMIC DRUGS FOR THE TREATMENT OF ATRIAL FIBRILLATION

    Oct 1, 2009, 00:00

  • PRS23 FRENCH GATEKEEPING COST-EFFECTIVENESS IMPACT ON CHRONIC PATIENTS TREATED WITH INHALED CORTICOSTEROIDS, IN REAL LIFE

    Oct 1, 2009, 00:00

  • PIH4 AVALIAO E HISTERECTOMIA

    Oct 1, 2009, 00:00

  • PND4 THE FEATURES OF MULTIPLE SCLEROSIS IN IRAN

    Oct 1, 2009, 00:00

  • PCN7 A COMPARISON OF CLINICAL EFFICACY AND SAFETY OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION AFTER MOBILIZATION WITH LENOGRASTIM AND FILGRASTIM

    Oct 1, 2009, 00:00

  • PIN3 HEPATOCELLULAR CARCINOMA (HCC) RISK ESTIMATION BASED ON CHRONIC HEPATITIS B (CHB) VIRAL LOAD LEVELS IN BRAZILIAN PATIENTS

    Oct 1, 2009, 00:00

  • PCN12 ECONOMIC EVALUATION OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS OF FEC-D VS FEC, IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO

    Oct 1, 2009, 00:00

  • PSS36 DEVELOPMENT AND VALIDATION OF THE PATIENT-REPORTED IMPACT OF SCARS MEASURE (PRISM)

    Oct 1, 2009, 00:00

  • PSY42 BLEEDING DISORDERS, MENORRHAGIA AND IRON DEFICIENCY- AN EXAMINATION OF QUALITY OF LIFE

    Oct 1, 2009, 00:00

  • PMH18 SCHIZOPHRENIA MODELING- FACTORS ASSOCIATED WITH THE RISK OF BEING IN A SPECIFIC DISEASE STATE

    Oct 1, 2009, 00:00

  • PDB79 DO PEOPLE BEGINNING BASAL INSULIN HAVE A DISTINCT CLINICAL PROFILE COMPARED WITH THE OVERALL POPULATION IN THE CREDIT STUDY?

    Oct 1, 2009, 00:00

  • PRS1 A COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE WITH BUDESONIDE AND BECLOMETHASONE IN 1-2 DOSE RATIO IN THE TREATEMENT OF BRONCHIAL ASTHMA

    Oct 1, 2009, 00:00

  • PCN43 THE COST OF TREATING GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN FRANCE

    Oct 1, 2009, 00:00

  • PMH9 VALIDATION OF PEER RELATIONS SCALE FOR ADOLESCENTS TREATED FOR SUBSTANCE USE DISORDER- AN APPLICATION OF RASCH MODELING

    Oct 1, 2009, 00:00

  • PCN74 COMPARISON OF THE COST-EFFECTIVENESS OF ZOLEDRONIC ACID THERAPY FOR RENAL CELL CARCINOMA (RCC) PATIENTS WITH BONE METASTASES IN FRENCH, GERMAN, AND THE UK POPULATIONS

    Oct 1, 2009, 00:00

  • PCN170 PUBLIC REGULATION OF THE CANCER DRUGS MARKET IN FRENCH HOSPITALS

    Oct 1, 2009, 00:00

  • PCN71 COST-EFFECTIVENESS OF RITUXIMAB COMBINED WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN FRANCE

    Oct 1, 2009, 00:00

  • PCN114 COST-EFFECTIVENESS ANALYSIS OF PEMETREXED/CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY- RESULTS FOR THE ADENOCARCINOMA HISTOLOGY SUB-POPULATION

    Oct 1, 2009, 00:00

  • PHP41 LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM- ASSESSING THE ADVERSE EFFECTS

    Oct 1, 2009, 00:00

  • PND7 BUDGET IMPACT AND COST-EFFECTIVENESS OF SUGAMMADEX IN THE REVERSAL OF PATIENTS WITH NEUROMUSCULAR BLOCK

    Oct 1, 2009, 00:00

  • PCV152 ASSESSING THE IMPACT OF A COMMUNITY PHARMACY BASED MTM PROGRAM ON OUTCOMES FOR EMPLOYEES WITH HYPERTENSION

    Oct 1, 2009, 00:00

  • PCN122 COST-EFFECTIVENESS ANALYSIS OF HORMONAL THERAPIES IN PATIENTS WITH ADVANCED PROSTATE CANCER IN ITALY

    Oct 1, 2009, 00:00

  • PMC38 COMPARISON OF TWO METHODS TO DETERMINE COSTS FOR AML PATIENTS IN REMISSION- MODEL VALIDATION FROM A UK PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIH11 REDUO PAULO

    Oct 1, 2009, 00:00

  • PUK5 THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL

    Oct 1, 2009, 00:00

  • PHP8 GASTOS COM MEDICAMENTOS E CARATERDE DE FORTALEZA EM 2007

    Oct 1, 2009, 00:00

  • PG116 RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH OPIOIDINDUCED CONSTIPATION (OIC) IN CANCER PATIENTS IN SWEDEN

    Oct 1, 2009, 00:00

  • PDB74 ETHICAL DILEMMAS OF PHARMACOLOGICAL TREATMENT AND SELF MANAGEMENT OF DIABETES-A REVIEW OF THE LITERATURE

    Oct 1, 2009, 00:00

  • PDB61 DIABETES REGIMEN UTILIZATION IN A LARGE MANAGED CARE SETTING; A COMPARISON WITH ADA/EASD CONSENSUS STATEMENT GUIDELINES

    Oct 1, 2009, 00:00

  • PG14 SYSTEMATIC REVIEW- THE CLINICAL EFFECTIVENESS OF ANTI-TNFALPHA DRUGS IN ADULTS WITH REFRACTORY CROHNS DISEASE

    Oct 1, 2009, 00:00

  • PRS37 IMPROVEMENTS IN QUALITY OF LIFE FOR PATIENTS UNDERGOING COPD REHABILITATION AT MUNICIPALITY HEALTH CARE CENTRES IN DENMARK

    Oct 1, 2009, 00:00

  • PIN18 IMPACTO EPIDEMIOLN DE LA VACUNA DE INFLUENZA EN COLOMBIA

    Oct 1, 2009, 00:00

  • CO2 ACCOUNTING FOR THE DRUG LIFE CYCLE AND FUTURE DRUG PRICES IN COST EFFECTIVENESS ANALYSIS

    Oct 1, 2009, 00:00

  • PHP85 RECOMMENDATIONS FOR THE USE OF PATIENT REPORTED OUTCOMES TO ASSESS TREATMENT EFFICACY IN CLINICAL GUIDANCE DOCUMENTS RELEASED BY THE FDA AND EMEA

    Oct 1, 2009, 00:00

  • PUK15 STRESS URINARY INCONTINENCE- ASSESSMENT OF WOMENS PREFERENCES

    Oct 1, 2009, 00:00

  • PDB6 EVALUACIN DE LA INSULINA- EL DILEMA DE LOS PAGADORES

    Oct 1, 2009, 00:00

  • PDB19 TIME TO OPIOID USE AND HEALTH CARE COSTS AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS

    Oct 1, 2009, 00:00

  • PND35 FACTORS DRIVING PATIENT SELECTION OF PRIMARY MEDICATION FOR MULTIPLE SCLEROSIS

    Oct 1, 2009, 00:00

  • PIH8 AUTOPERCEPCIN DE EQ-5D Y DE LA ESCALA VISUAL ANALOGA

    Oct 1, 2009, 00:00

  • PSY47 VALIDATION OF THE FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY (FACIT)-FATIGUE SCALE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

    Oct 1, 2009, 00:00

  • PDB11 DATABASE ANALYSIS ON PREVALENCE AND RISK FACTORS OF DIABETIC FOOT SYNDROME (DFS) IN GERMANY

    Oct 1, 2009, 00:00

  • MO9 HANDLING UNCERTAINTY IN THE CASE OF COMBINED END-POINTS

    Oct 1, 2009, 00:00

  • PDB31 COST-EFFECTIVENESS ANALYSIS OF VOGLIBOSE FOR PREVENTION OF TYPE-2 DIABETES MELLITUS IN JAPANESE INDIVIDUALS WITH IMPAIRED GLUCOSE TOLERANCE

    Oct 1, 2009, 00:00

  • PND13 IMPACT OF CHRONIC (CM) AND EPISODIC MIGRAINE (EM) ON WORK PRESENTEEISM IN 9 COUNTRIES

    Oct 1, 2009, 00:00

  • PCV28 BALANCING EFFICACY AND SAFETY OF PRASUGREL VS. CLOPIDOGREL IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION- A POPULATION ANALYSIS OF NET CLINICAL BENEFIT

    Oct 1, 2009, 00:00

  • PSY54 COST-EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY FOR GAUCHERS DISEASE IN THE URAL ADMINISTRATION DISTRICT OF RUSSIA FEDERATION

    Oct 1, 2009, 00:00

  • PCV137 PREFERENCES OF PATIENTS, PHYSICIANS AND CAREGIVERS IN THE CHOICE OF ABDOMINAL AORTIC ANEURYSMS TREATMENT OPTIONS- THE PREFER STUDY

    Oct 1, 2009, 00:00

  • PND21 COST-EFFECTIVENESS OF RASAGILINE COMPARED TO OTHER FIRST LINE TREATMENT OPTIONS OF EARLY PARKINSONS DISEASE IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PHP12 SHORTAGES IN THE AMERICAN MEDICAL DRUG MARKET

    Oct 1, 2009, 00:00

  • PMH13 TIME TO OPTIMIZATION OF DOSE IN PATIENTS WITH ATTENTIONDEFICIT/ HYPERACTIVITY DISORDER (ADHD)- DATA FROM THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PSY17 COSTS OF FIBROMYALGIA- RESULTS FROM A CROSS-SECTIONAL STUDY IN GERMANY

    Oct 1, 2009, 00:00

  • PCN34 BUDGET IMPACT ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) IN BRAZIL

    Oct 1, 2009, 00:00

  • PMS51 COST-MINIMIZATION ANALYSIS OF IV BISPHOSPHONATES FOR RISK REDUCTION OF POST-MENOPAUSE VERTEBRAL AND NON-VERTEBRAL FRACTURES UNDER THE PRIVATE PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PSY38 ELICITING HEALTH STATE UTILITIES FOR IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA- RESULTS OF A GENERAL PUBLIC BASED TIME TRADE-OFF SURVEY

    Oct 1, 2009, 00:00

  • PDB34 LOWER LONG-TERM COSTS IN GERMAN TYPE-2-DIABETICS STARTING A BASAL SUPPORTED ORAL THERAPY (BOT) WITH INSULIN GLARGINE COMPARED TO NPH-INSULIN

    Oct 1, 2009, 00:00

  • PRS32 ADJUSTING THE NICOTINE DOSE- THE KEY TO A SUCCESSFUL, 'TAILORED' METHOD OF QUITTING SMOKING

    Oct 1, 2009, 00:00

  • PMS1 BUDGET IMPACT ANALYSIS OF ZOLEDRONIC ACID IN POST MENOPAUSAL OSTEOPOROSIS BY BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Oct 1, 2009, 00:00

  • PHP87 COST-EFFECTIVENESS OF HEALTH PROMOTING INTERVENTIONS

    Oct 1, 2009, 00:00

  • MH3 ANTIPSYCHOTIC USE AND DIABETES- A NESTED CASE-CONTROL ANALYSIS IN A COHORT OF NEW ANTIPSYCHOTIC USERS

    Oct 1, 2009, 00:00

  • PCN95 COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN METASTATIC COLORECTAL CANCER- RESULTS OF MARKOV COHORT SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA

    Oct 1, 2009, 00:00

  • PCV136 HEALTH STATE UTILITY VALUES FOR ATRIAL FIBRILLATION AND ASSOCIATED TREATMENT-RELATED ADVERSE EVENTS

    Oct 1, 2009, 00:00

  • PIH43 EARLY ASSESSMENT OF A NEW TREATMENT FOR ADOLESCENT IDIOPATHIC SCOLIOSIS

    Oct 1, 2009, 00:00

  • PIN57 A COMPARISON OF THE COST-EFFECTIVENESS OF THE 13-VALENT (PCVI3) AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN THE UK

    Oct 1, 2009, 00:00

  • PHP9 HELSPORS ASSESSMENT OF THE PHARMACEUTICAL POLICY REFORMS IN GREECE- COST-CONTAINMENT AND ECONOMIC EVALUATION CRITERIA

    Oct 1, 2009, 00:00

  • PMS65 IMPACT OF MINIMAL ACCESS SPINAL TECHNOLOGIES (MAST) ON HOSPITALIZATION COST- A FRENCH EXPERIENCE

    Oct 1, 2009, 00:00

  • PCV21 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF COMBINATION THERAPIES CONTAINING ARBS VERSUS ACE INHIBITORS

    Oct 1, 2009, 00:00

  • PMC22 DEVELOPMENT OF A SENSITIVE RESOURCE USE QUESTIONNAIRE

    Oct 1, 2009, 00:00

  • PCN38 NUMBER NEEDED TO TREAT (NNT) TO AVOID ONE GASTROINTESTINAL STROMAL TUMOUR (GIST) RECURRENCE IN BRAZIL. COST COMPARISON AND BUDGET IMPACT ANALYSIS OF ADJUVANT TREATMENT WITH IMATINIB

    Oct 1, 2009, 00:00

  • PHP38 HOSPITALIZATION COST OF PATIENTS ADMITTED TO THE TEACHING UNIVERSITY HOSPITAL OF LARISSA (TUHL) IN THE REGION OF THESSALY

    Oct 1, 2009, 00:00

  • PMS5 A SYSTEMATIC REVIEW AND MIXED TREATMENT COMPARISON (MTC) OF THE EFFICACY OF PHARMACOLOGICAL TREATMENTS FOR FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PCN86 THE COST-EFFECTIVENESS OF BORTEZOMIB FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA-A NORDIC COMPARISON

    Oct 1, 2009, 00:00

  • PND49 MIGRAINE- PRESCRIBING PATTERNS IN A SOUTH AFRICAN PRIMARY CARE PATIENT POPULATION

    Oct 1, 2009, 00:00

  • PCV22 CLINICAL EFFICACY OF IMPLANTABLE LOOP RECORDER IN ESTABLISHING THE CAUSES OF UNEXPLAINED OR RECURRENT SYNCOPES

    Oct 1, 2009, 00:00

  • PSY5 IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS

    Oct 1, 2009, 00:00

  • PMH17 PREVALENCE, INCIDENCE AND PERSISTENCE OF ANTIDEPRESSANT DRUG PRESCRIBING IN THE ITALIAN GENERAL POPULATION- RETROSPECTIVE DATABASE ANALYSIS

    Oct 1, 2009, 00:00

  • PHP79 A REVIEW OF THE USE OF PROS IN SUBMISSIONS TO NICE

    Oct 1, 2009, 00:00

  • MO8 MARGINAL STRUCTURAL MODELS FOR COMPARING THE EFFECTIVENESS OF MULTIPLE TREATMENTS IN OBSERVATIONAL STUDIES

    Oct 1, 2009, 00:00

  • UT4 DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-LEVEL VERSION OF EQ-5D

    Oct 1, 2009, 00:00

  • EE6 INCORPORATING EQUITY IN COST-EFFECTIVENESS ANALYSIS- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PMH5 COST-EFFECTIVENESS OF RISPERIDONE LONG-ACTING INJECTABLE VERSUS QUETIAPINE IN SCHIZOPHRENIC PATIENTS

    Oct 1, 2009, 00:00

  • PMC4 LARGELY IGNORED- THE IMPACT OF THE THRESHOLD VALUE FOR A QALY ON THE IMPORTANCE OF A TRANSFERABILITY FACTOR

    Oct 1, 2009, 00:00

  • PSY16 THE DIRECT AND INDIRECT COSTS OF THE ANKYLOSING SPONDYLITIS IN THE CZECH REPUBLIC-COMPARISON BETWEEN 2005 AND 2008 STUDIES

    Oct 1, 2009, 00:00

  • PSS17 A HEALTH ECONOMIC EVALUATION OF ELIMINATING NONCOMPLIANCE WITH ORAL TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS IN DOGS IN GERMANY

    Oct 1, 2009, 00:00

  • PHP40 THE CONCENTRATION OF PHARMACEUTICAL MARKET IN SOME MEDICINE GROUPS IN FINLAND

    Oct 1, 2009, 00:00

  • PCN164 TWO DIFFERENT DOSES OF PALONOSETRON (PAL) FOR PREVENTION OF CHEMOTHERAPY-INDUCED VOMITING (CIV) IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) TREATMENT- SYSTEMATIC REVIEW (SR) AND META-ANALYSIS (MA)

    Oct 1, 2009, 00:00

  • PSS29 ADHERENCE TO ANTIGLAUCOMA DRUG TREATMENT IN NEWLY TREATED PATIENTS

    Oct 1, 2009, 00:00

  • PMC28 EXPERT SURVEY FOR INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) THRESHOLD RANGE IN KOREA- DISCRETE CHOICE EXPERIMENTS

    Oct 1, 2009, 00:00

  • PHP43 INTERNATIONAL PAYER RESARCH- COMPARING AND CONTRASTING PAYER ROLES AND RESEARCH METHODS IN CANADA, SPAIN, AND THE UK

    Oct 1, 2009, 00:00

  • PCV90 PATIENTS ADMITTED TO THE ICU AFTER CARDIOPULMONARY RESUSCITATION- AN ANALYSIS OF OUTCOME, QUALITY OF LIFE AND COST-EFFECTIVENESS

    Oct 1, 2009, 00:00

  • PSS43 EVALUATION OF THE IMPLEMENTATION OF UK NATIONAL GUIDANCE ON THE USE OF BIOLOGICS IN SEVERE PSORIASIS

    Oct 1, 2009, 00:00

  • CASE3 THE SLOVAK EXPERIENCE IN THE INTERNATIONAL PRICE BENCHMARKING FOR PRESCRIPTION DRUGS

    Oct 1, 2009, 00:00

  • PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HE ...

    Oct 1, 2009, 00:00

  • PCV23 CALIDAD DE VIDA RELACIONADA CON LA SALUD EN PACIENTES CON RIESGO CARDIOVASCULAR

    Oct 1, 2009, 00:00

  • PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY

    Oct 1, 2009, 00:00

  • PND8 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Oct 1, 2009, 00:00

  • PIH14 THE COST-EFFECTIVENESS OF ETONOGESTREL/ETHINYL ESTRADIOL VAGINAL RING IN SCOTLAND

    Oct 1, 2009, 00:00

  • PSS7 THE APPLICATION OF DISCRETE EVENT SIMULATION TO QUANTITATIVE RISK BENEFIT ANALYSIS

    Oct 1, 2009, 00:00

  • PHP17 CAN ELECTRONIC NOTIFICATIONS ABOUT SUBSTITUTES CHANGE PHYSICIANS DRUG PRESCRIPTION HABITS? DEFINITELY YES!

    Oct 1, 2009, 00:00

  • PSY3 DETERMINING THE COST OF OBESITY AND ITS MAJOR COMORBIDITIES FROM A COMMERCIAL CLAIMS DATABASE

    Oct 1, 2009, 00:00

  • PDB52 PATIENT TREATMENT SATISFACTION OF TYPE 2 DIABETIC PATIENTS TREATED WITH A BASAL-BOLUS REGIMEN USING INSULINS GLARGINE OR DETEMIR AS BASAL INSULIN- RESULTS FROM THE LIVE-COM STUDY

    Oct 1, 2009, 00:00

  • PCV71 PREVALENCE AND ECONOMIC BURDEN OF HYPERTENSION IN PATIENTS WITH METABOLIC SYNDROME IN SPAIN- AN EPIDEMIOLOGICAL COST-OF-ILLNESS MODEL

    Oct 1, 2009, 00:00

  • CS6 THE INTRODUCTION OF PRE-ENDOSCOPY (EGD) HIGH-DOSE INTRAVENOUS PROTON PUMP INHIBITION (HDIVPPI) IN THE MANAGEMENT OF PATIENTS WITH ACUTE UPPER GASTROINTESTINAL BLEEDING (UGIB)-A BUDGET IMPACT ANALYSIS

    Oct 1, 2009, 00:00

  • PCV54 EXAMINING THE COST IMPACTS OF RECONFIGURING TIA CARE IN SPAIN

    Oct 1, 2009, 00:00

  • PCV2 INCREASED RISK OF MORTALITY AND CO-MORBIDITIES IN PATIENTS WITH UNTREATED PRIMARY HYPERPARATHYROIDISM

    Oct 1, 2009, 00:00

  • PCV22 EFFECTS OF TADALAFIL ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

    Oct 1, 2009, 00:00

  • PMC62 ONLINE ADMINISTRATION OF THE TIME TRADE-OFF- A CASE-STUDY AMONG PEOPLE WITH RESTLESS LEGS SYNDROME

    Oct 1, 2009, 00:00

  • PSY6 EFFECT OF MODERATE-INTENSITY EXERCISE TRAINING AND DIET ON BODY COMPOSITION AND EXERCISE CAPACITY IN OBESE CHILDREN

    Oct 1, 2009, 00:00

  • PG13 INTRAVENOUS (IV) PROTON PUMP INHIBITORS (PPIS) FOR THE TREATMENT OF PEPTIC ULCER BLEEDING (PUB)

    Oct 1, 2009, 00:00

  • PCV67 A COST-OF-ILLNESS ANALYSIS OF ATRIAL FIBRILLATION IN SWEDEN

    Oct 1, 2009, 00:00

  • PCV57 COSTS OF ATRIAL FIBRILLATION IN SLOVAKIA FROM A PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PMS9 COST-MINIMIZATION ANALYSIS OF VISCOSUPPLEMENTATION TREATMENT OSTEOARTHRITIS OF KNEE IN BRAZILS PRIVATE SECTOR

    Oct 1, 2009, 00:00

  • PCV131 NONADHERENCE AND DISCONTINUATION OF LOW-DOSE ACETYLSALICYLIC ACID IN PATIENTS WITH CARDIOVASCULAR RISK- THE IMPACT OF GASTROINTESTINAL SYMPTOMS

    Oct 1, 2009, 00:00

  • PIN81 MODELING AND SIMULATION OF EPIDEMIOLOGIC EFFECTS OF PENUMOCOCCAL CHILDREN VACCINATION IN AUSTRIA USING CLASSICAL MARKOVIAN METHODS AND DIFFERENTIAL EQUATIONS

    Oct 1, 2009, 00:00

  • PSY4 ECONOMIC EVALUATION OF METFORMIN, METFORMIN SIBUTRAMIN OR ACARBOSE IN THE MANAGEMENT OF OVERWEIGHT AND OBESE DIABETES PATIENTS

    Oct 1, 2009, 00:00

  • CS7 COST-EFFECTIVENESS AND BUDGET IMPACT OF INTRODUCING ROSUVASTATIN INTO THE BRAZILIAN NATIONAL DRUG FORMULARY

    Oct 1, 2009, 00:00

  • PMC60 WILLINGNESS TO PAY FOR HEALTH INTERVENTIONS- BASED ON SYSTEMATIC REVIEW OF LITERATURES

    Oct 1, 2009, 00:00

  • PMS21 MIXED TREATMENT COMPARISONS- AN EVIDENCE-BASED BUDGET IMPACT MODEL OF RITUXIMAB (MABTHERA) AFTER FAILURE OF ONE OR MORE TNF INHIBITOR THERAPIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Oct 1, 2009, 00:00

  • VA5 INDIVIDUALLY-BASED DYNAMIC MODELING OF INFECTIOUS DISEASES- COST-EFFECTIVENESS OF ADOLESCENT PERTUSSIS BOOSTER VACCINATION FOR THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN133 POPULATION PREFERENCES FOR TREATMENT OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA

    Oct 1, 2009, 00:00

  • PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY- A SENSITIVITY ANA ...

    Oct 1, 2009, 00:00

  • DE2 INFLUENCE OF GENERIC DRUGS ON PROTON PUMP INHIBITOR PRESCRIPTION IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PCN35 BUDGETARY IMPACT OF ORAL CHEMOTHERAPY- REAL-WORLD DATA ANALYSIS FROM PAYERS PERSPECTIVES IN BRAZIL

    Oct 1, 2009, 00:00

  • PRS21 COST-EFFECTIVENESS ANALYSIS OF XOLAIR UNDER REAL LIFE CONDITIONS IN BELGIAN PATIENTS WITH SEVERE ALLERGIC ASTHMA

    Oct 1, 2009, 00:00

  • PIN7 COSTO-BENEFICIO DEL USO DE TIGECICLINA VS. TRIPLE ESQUEMA ANTIMICROBIANO CEFOTAXIMA/AMIKACINA/METRONIDAZOL EN PACIENTES CON INFECCIONES INTRAABDOMINALES Y DE PIEL Y TEJIDOS BLANDOS EN MXICO

    Oct 1, 2009, 00:00

  • PIN17 THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN IN FOUR EUROPEAN COUNTRIES- A STUDY IN PRIMARY CARE

    Oct 1, 2009, 00:00

  • PSS3 TREATMENT PERSISTENCY OF XALATAN-XALACOM, LUMIGANGANFORT AND TRAVATAN-DUOTRAV- AN ANALYSIS CONDUCTED ON THE UNITED-KINGDOM GENERAL PRACTITIONER RESEARCH DATABASE

    Oct 1, 2009, 00:00

  • PDB29 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENS UNDERGOING DIABETIC END-STAGE RENAL DISEASE

    Oct 1, 2009, 00:00

  • PIN71 QUALITY OF LIFE (QOL) AND OTHER ENDPOINTS COMPARISON IN THE TREATMENT OF FACIAL LIPOATROPHY WITH INJECTION OF POLY-L-LACTIC ACID

    Oct 1, 2009, 00:00

  • PG112 RESOURCE UTILIZATION AND DIRECT MEDICAL COST OF CHRONIC HEPATITIS C (CHC) IN THAILAND- A HEAVY BUT MANAGEABLE ECONOMIC BURDEN

    Oct 1, 2009, 00:00

  • PIN41 PREVENTION OF AN INFLUENZA PANDEMIC IN MEXICO- ESTABLISHING A COST-EFFECTIVE ALTERNATIVE FOR ELDERLY POPULATION

    Oct 1, 2009, 00:00

  • PMS92 EXPOSURE TO OSTEOPOROSIS MEDICATION IN MEN

    Oct 1, 2009, 00:00

  • PDB70 ORAL MEDICATIONS VS INSULIN FOR DIABETES- EPIDEMIOLOGICAL HEALTH POLICY IMPLICATIONS IN GREECE

    Oct 1, 2009, 00:00

  • PCV169 ACETYLSALICYLIC ACID(ASA) MONOTHERAPY FOR SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASE- AN ASSESSMENT OF THE MEDICAL BENEFIT USING THE IQWIG METHODOLOGICAL APPROACH

    Oct 1, 2009, 00:00

  • PMS87 IMPACT OF RHEUMATOID ARTHRITIS (RA) ON WORKING CONDITIONS AND INCOME

    Oct 1, 2009, 00:00

  • PND10 COST ANALYSIS OF ACTIVA RC- RECHARGABLE NEUROESTIMULATOR FOR DEEP BRAIN ESTIMULATION THERAPY (DBS)

    Oct 1, 2009, 00:00

  • VA1 SEVEN, TEN OR THIRTEEN? THE COST-UTILITY OF INFANT VACCINATION WITH A 7-, 10- OR 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PCN15 ECONOMIC EVALUATION OF TEMOZOLOMIDE FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN MEXICO

    Oct 1, 2009, 00:00

  • PHP5 RISK OF DEATH AND HOSPITAL LENGTH OF STAY ASSOCIATED WITH CLINICAL EVENTS POTENTIALLY CAUSED BY NEUROMUSCULAR BLOCKADE REVERSAL AGENTS

    Oct 1, 2009, 00:00

  • PND36 HEALTH-RELATED QUALITY OF LIFE, EDSS AND TIMED 25-FOOT WALK IN A MULTIPLE SCLEROSIS POPULATION OF A REAL-WORLD OBSERVATIONAL OUTCOMES STUDY- BASELINE DATA FROM ROBUST

    Oct 1, 2009, 00:00

  • PMS64 ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, ANHEMIA

    Oct 1, 2009, 00:00

  • PIN51 COST-EFFECTIVENESS STUDY OF THE USE OF DAPTOMYCIN VERSUS VANCOMYCIN IN INFECTIVE ENDOCARDITIS AND BACTEREMIA TREATMENT IN PUBLIC HEALTH INSTITUTIONS IN MEXICO

    Oct 1, 2009, 00:00

  • EE4 MARKET ACCESS IN GERMANY- WHERE NEXT?

    Oct 1, 2009, 00:00

  • MO10 EARLY MODELLING- METHODS IN THE ECONOMIC ANALYSIS OF PRE-PHASE II PRODUCTS

    Oct 1, 2009, 00:00

  • PCV155 IMPACT OF EXPANDING PHARMACY BENEFITS ON TREATMENT OF CONGESTIVE HEART FAILURE- THE CASE OF MEDICARE PART D

    Oct 1, 2009, 00:00

  • PMC36 CREATING NATIONAL WEIGHTS FOR PRIVATE INSURANCE DATABASE

    Oct 1, 2009, 00:00

  • PIN73 CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLAND

    Oct 1, 2009, 00:00

  • PCN32 IMPLEMENTATION OF CLINICAL INTERVENTION REPORTING SYSTEM FOR PHARMACISTS

    Oct 1, 2009, 00:00

  • PSS41 DEVELOPMENT AND ACCEPTABILITY OF A NEW INTERNATIONAL QUALITY OF LIFE INSTRUMENT SPECIFIC TO PHYSICAL APPEARANCE- BEAUTYQOL

    Oct 1, 2009, 00:00

  • PCN82 COST-EFFECTIVENESS ANALYSIS OF HPV VACCINATION IN SLOVENIA

    Oct 1, 2009, 00:00

  • PSY37 IMPACT OF TOLVAPTAN ON SELF-REPORTED UTILITY SCORES IN HYPONATREMIC PATIENTS

    Oct 1, 2009, 00:00

  • MO3 R THERE ANY DIFFERENCES BETWEEN EXCEL AND R? COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND R

    Oct 1, 2009, 00:00

  • VA7 COMPARISON OF DIFFERENT STATIC AND DYNAMIC SIMULATION TECHNIQUES FOR THE INFLUENCE OF CHILDREN PNEUMOCOCCAL VACCINATION

    Oct 1, 2009, 00:00

  • PRS36 XOLAIR QUALITY OF LIFE RESULTS AS MEASURED IN A BELGIAN OBSERVATIONAL STUDY IN PATIENTS WITH SEVERE ALLERGIC ASTHMA

    Oct 1, 2009, 00:00

  • PMH75 PREDICTORS AND COSTS OF MDD TREATMENT WITH DULOXETINE COMPARED WITH VENLAFAXINE EXTENDED RELEASE

    Oct 1, 2009, 00:00

  • PCV60 BUDGET IMPACT MODEL FOR DETERMINING THE HOSPITAL COSTS OF INTRODUCING PRASUGREL FOR THE LONG TERM TREATMENT OF ACUTE CORONARY SYNDROME TREATED BY PERCUTANEOUS CORONARY INTERVENTION IN FRANCE

    Oct 1, 2009, 00:00

  • PCN141 QUALITY OF LIFE (QOL) IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) FROM THE AVADO STUDY- THE IMPORTANCE OF IMPUTATION METHODS FOR HANDLING MISSING DATA

    Oct 1, 2009, 00:00

  • PSY26 ECONOMIC EVALUATION OF THE ADDITION OF RITUXIMAB TO CVP FOR ADVANCED FOLLICULAR LYMPHOMA IN ROMANIA

    Oct 1, 2009, 00:00

  • PUK4 THE IMPACT ON COSTS OF TREATING COMPLICATIONS DUE TO CRONIC KIDNEY DISEASE IN PATIENTS UNDERGOING HEMODIALYSIS IN THE PUBLIC HEALTH CARE SYSTEM IN BRAZIL

    Oct 1, 2009, 00:00

  • PCV78 ONE-YEAR HEALTH CARE COSTS FOR ACUTE CORONARY SYNDROME PATIENTS WITH DIFFERENT TREATMENT STRATEGIES DURING THE INITIAL HOSPITALIZATION

    Oct 1, 2009, 00:00

  • PHP7 BED OCCUPANCY RATE OF HUNGARIAN INTENSIVE CARE UNITS

    Oct 1, 2009, 00:00

  • VA8 HOW SHOULD HEALTH GAINS OF VACCINATION STRATEGIES BE DISCOUNTED?

    Oct 1, 2009, 00:00

  • PUK7 ANALYSIS OF THE PHARMACOTHERAPY COST OF PATIENTS WITH KIDNEY TRANSPLANTATION IN BULGARIA

    Oct 1, 2009, 00:00

  • PND25 COST-EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATE TO SEVERE ALZHEIMERS DISEASE IN NORWAY

    Oct 1, 2009, 00:00

  • MC4 COMPARISON OF DATA AVAILABILITY AND QUALITY FOR PHARMACOECONOMIC ANALYSIS IN BRAZIL VERSUS THE UNITED STATES AND EUROPEAN UNION- THE CASES OF DIABETES HYPERTENSION

    Oct 1, 2009, 00:00

  • PCV12 COST-EFFECTIVENESS ANALYSIS OF DABIGATRAN ETEXILATE VERSUS ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCN17 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF IMIQUIMOD 5% CREAM FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA

    Oct 1, 2009, 00:00

  • PMS28 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA

    Oct 1, 2009, 00:00

  • PHP22 TOO MANY AGENCIES FOR DRUG EVALUATION IN SPAIN?

    Oct 1, 2009, 00:00

  • PCV104 THE COST-EFFECTIVENESS ANALYSIS IN SCREENING OF DEEP VEIN THROMBOSIS IN A CLINICAL LABORATORY

    Oct 1, 2009, 00:00

  • PCN153 PERFORMANCE MONITORING OF ORGANIZED CANCER SCREENING PROGRAMMES USING ADMINISTRATIVE DATA

    Oct 1, 2009, 00:00

  • PCV8 PREVALENCE OF PERIPHERAL ARTERIAL DISEASE IN SUBJECTS WITH A MODERATE CVD RISK, WITH NO OVERT VASCULAR DISEASES NOR DIABETES MELLITUS. THE PANDORA SURVEY-BELGIUM RESULTS

    Oct 1, 2009, 00:00

  • PMH76 PREDICTORS FOR DULOXETINE TREATMENT FOR PATIENTS WITH MAJOR DEPRESSIVE DISORDER IN VETERANS AFFAIRS HEALTH CARE NETWORK

    Oct 1, 2009, 00:00

  • PCV158 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM- USAGE IN CROATIA DURING A SEVEN-YEAR PERIOD

    Oct 1, 2009, 00:00

  • PDB4 LONG-TERM OUTCOMES OF SWITCHING PATIENTS WITH TYPE 2 DIABETES FROM BIPHASIC INSULIN TO BIPHASIC INSULIN ASPART 30/70- AN IMPROVE STUDY SUBGROUP ANALYSIS

    Oct 1, 2009, 00:00

  • PCV8 COST OF ILLNESS IN PATIENTS WITH PULMONARY EMBOLISM AFTER ELECTIVE TOTAL HIP REPLACEMENT

    Oct 1, 2009, 00:00

  • PIH1 MEDICAMENTOS POTENCIALMENTE INAPROPIADOS EN ADULTOS MAYORES ATENDIDOS EN ATENCIN PRIMARIA DE SALUD

    Oct 1, 2009, 00:00

  • PGI5 WHAT ARE THE COSTS FOR NON-COMPLIANCE WITH GUIDELINES FOR TREATMENT OF CHRONIC HEPATITIS C?

    Oct 1, 2009, 00:00

  • PIN11 BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES FOR TREATMENT OF HIV PATIENTS IN BULGARIA

    Oct 1, 2009, 00:00

  • PCN21 ESTUDIO DE COSTO EFECTIVIDAD DEL USO DE TRASTUZUMAB COMO TRATAMIENTO ADYUVANTE DEL CA DE COLOMBIA, DESDE EL PUNTO DE VISTA DEL PAGADOR

    Oct 1, 2009, 00:00

  • PCN87 A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY

    Oct 1, 2009, 00:00

  • PMH60 A CONCEPTUAL MODEL OF RELEVANT TO PATIENTS DIAGNOSED WITH SCHIZOPHRENIA

    Oct 1, 2009, 00:00

  • PMH45 COST-UTILITY OF AGOMELATINE, VENLAFAXINE AND PLACEBO IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN FINLAND-ECONOMIC MODELLING STUDY USING REPRESENTATIVE POPULATION DATA

    Oct 1, 2009, 00:00

  • PIN16 COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO

    Oct 1, 2009, 00:00

  • PDB43 MEDICATION ADHERENCE IN LOW INCOME ELDERLY TYPE 2 DIABETES PATIENTS- A RETROSPECTIVE COHORT STUDY

    Oct 1, 2009, 00:00

  • PMS62 INDIRECT COSTS OF RHEUMATOID ARTHRITIS AND THEIR DETERMINANTS

    Oct 1, 2009, 00:00

  • PCN132 UTILITY LIBRARY TO CAPTURE UTILITIES IN THE AREA OF ONCOLOGY

    Oct 1, 2009, 00:00

  • CS1 COST-EFFECTIVENESS ANALYSIS OF A CERVICAL CANCER VACCINE IN FIVE LATIN AMERICAN COUNTRIES

    Oct 1, 2009, 00:00

  • PMC24 SAMPSON- A HYBRID SIMULATION AND OPTIMIZATION MODEL FOR MANAGING SURGICAL RESOURCES AND REDUCING WAITING TIMES

    Oct 1, 2009, 00:00

  • PDB26 THE PHARMACOECONOMIC STUDY OF INSULIN GLRAGINE USAGE IN ROUTINE CLINICAL PRACTICE IN RUSSIAN FEDERATION

    Oct 1, 2009, 00:00

  • WP1 COMPARISON OF A DIRECT AND AN INDIRECT METHOD TO DERIVE WILLINGNESS TO PAY FOR COMPLEX HEALTH STATES IN OBSTETRICS

    Oct 1, 2009, 00:00

  • PSY4 CHALLENGES IN USING THE LITERATURE TO ESTIMATE THE OUTCOMES OF CURRENT RISK STRATIFICATION METHODS IN ADULT PATIENTS WITH PRIMARY ACUTE MYELOID LEUKEMIA

    Oct 1, 2009, 00:00

  • MC8 COMPARISON OF METHODS- FOR IDENTIFYING DEPRESSION IN PATIENTS WITH DIABETES USING PHYSIOLOGIC, SOCIAL, AND DISEASE SEVERITY MEASURES

    Oct 1, 2009, 00:00

  • PCV48 A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTICOAGULATION STRATEGIES IN PERCUTANEOUS CORONARY INTERVENTION

    Oct 1, 2009, 00:00

  • PCV7 ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES

    Oct 1, 2009, 00:00

  • PHP19 APPLYING 'VALUE BASED' PRICING TO REGENERATIVE MEDICINE BASED PHARMACEUTICALS

    Oct 1, 2009, 00:00

  • PMS79 IS BODY-MASS-INDEX A PREDICTIVE FACTOR FOR CLINICAL OUTCOME IN PATIENTS WITH MONOSEGMENTAL LUMBAR FUSION?

    Oct 1, 2009, 00:00

  • PDB4 COST OF TYPE 2 DIABETES COMPLICATIONS IN MEXICO

    Oct 1, 2009, 00:00

  • MO4 BAYESIAN GENERALIZED LINEAR MODELLING OF THE RELATIONSHIP BETWEEN HEALTH ASSESSMENT QUESTIONNAIRE-DISABILITY INDEX AND HEALTH UTILITIES INDEX MARK III IN EARLY AND LATE RHEUMATOID ARTHRITIS- DATA FROM THE PREMIER AND ARMADA TRIALS

    Oct 1, 2009, 00:00

  • PSS10 COST OF MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN

    Oct 1, 2009, 00:00

  • PDB58 THE 'WHO, HOW AND THEN WHAT' OF INSULIN INITIATION IN UK PRIMARY CARE

    Oct 1, 2009, 00:00

  • PCV94 THE COST-EFFECTIVENESS OF TITRATION TO GOAL WITH BRAND ROSUVASTATIN COMPARED TO GENERIC SIMVASTATIN IN PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL- PRIMARY AND SECONDARY PREVENTION IN THE BELGIAN HEALTH CARE SETTING

    Oct 1, 2009, 00:00

  • CASE2 EXPERIDE SUPLEMENTAR

    Oct 1, 2009, 00:00

  • PSS32 VALIDATION AND ASSESSMENT OF MEASUREMENT INVARIANCE OF THE EYELASH SATISFACTION QUESTIONNAIRE (ESQ) IN US CANCER PATIENTS

    Oct 1, 2009, 00:00

  • PRS34 ITEM SELECTION AND SCORING DEFINITION OF A DISEASE-SPECIFIC INSTRUMENT TO ASSESS THE HANDICAP IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PATIENTS, FOR USE IN CLINICAL ROUTINE PRACTICE

    Oct 1, 2009, 00:00

  • PND6 ESTIMATION OF PER-MEMBER-PER-YEAR COSTS FOR MANAGING FALLS OR FRACTURES AMONG HYPNOTIC USERS IN A MANAGED CARE PLAN

    Oct 1, 2009, 00:00

  • PIN20 LONG-TERM CONSEQUENCES OF AN INTENSE RUBELLA VACCINATION PROGRAM IN FORTALEZA, BRAZIL- A COST-EFFECTIVENESS ANALYSIS

    Oct 1, 2009, 00:00

  • PCV1 PREDICTED CARDIOVASCULAR EVENT REDUCTION WITH THE COADMINISTRATION OF FENOFIBRIC ACID AND LOW- OR MODERATEDOSE STATINS IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

    Oct 1, 2009, 00:00

  • PDB68 A RETROSPECTIVE ANALYSIS OF MEDICATION USE, RESOURCE UTILIZATION, AND CLINICAL EFFECTIVENESS OF EXENATIDE COMPARED TO GLARGINE IN PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • PHP78 THE ROLE OF HTA AGENCY IN DRUG REIMBURSEMENT DECISION-MAKING PROCESS IN POLAND (HTA IMPACT)

    Oct 1, 2009, 00:00

  • PCV87 COST-EFFECTIVENESS OF PRASUGREL VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND PLANNED PCI- RESULTS FROM THE TRITON-TIMI 38 TRIAL FROM THE GERMAN PERSPECTIVE

    Oct 1, 2009, 00:00

  • PSS33 DEVELOPMENT OF A NEW MEASURE FOR ASSESSING HEALTHRELATED QUALITY OF LIFE IN PATIENTES WITH PSOARIASIS- PSO-LIFE'

    Oct 1, 2009, 00:00

  • PMC51 PATIENT COMPLETION OF EPROS- TO PHONE OR TO WEB?

    Oct 1, 2009, 00:00

  • PMC50 MEASUREMENT OF OUTPATIENT REHABILITATION OUTCOMES WITH EQ-5D

    Oct 1, 2009, 00:00

  • PIN6 COSTS OF NOSOCOMIAL PNEUMONIA IN A THIRD LEVEL HOSPITAL OF MEXICAN SOCIAL SECURITY INSTITUTE (IMSS)

    Oct 1, 2009, 00:00

  • PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL- RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS ...

    Oct 1, 2009, 00:00

  • PMC44 MODELLING THE UPTAKE AND DIFFUSION OF INNOVATIVE TECHNOLOGY- A CRITICAL AND STRATEGIC FEATURE OF BUDGET IMPACT ANALYSIS AND RISK-SHARING AGREEMENTS

    Oct 1, 2009, 00:00

  • PCN98 COST-EFFECTIVENESS OF PROGNOSIS-BASED STRATEGIES TO SELECT WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY

    Oct 1, 2009, 00:00

  • PDB54 ASSESSING THE BURDEN OF ACROMEGALY- A REVIEW OF HEALTH-RELATED QUALITY OF LIFE AND ECONOMICS

    Oct 1, 2009, 00:00

  • PMC9 REDUCING BIAS IN A RETROSPECTIVE CASE-CONTROL STUDY- AN APPLICATION OF PROPENSITY SCORE MATCHING

    Oct 1, 2009, 00:00

  • PHP39 COST MEASURE IN PRIMARY CARE- RETROSPECTIVE BEHAVIOUR OF ACG CASE-MIX SYSTEM AT A SPANISH INTERREGIONAL LEVEL

    Oct 1, 2009, 00:00

  • PCN7 METASTATIC BREAST CANCER TREATMENT PATTERNS AND COSTS OF OUTPATIENT CARE UNDER THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PRS46 OFF-LABEL PRESCRIBING OF INHALED CORTICOSTEROID/ LONG ACTING BETA-AGONIST COMBINATION PRODUCTS IN COPD PATIENTS

    Oct 1, 2009, 00:00

  • PCV163 GENDER-BASED DIFFERENCES IN HEALTH CARE COSTS AMONG ACS PATIENTS- AN APPLICATION OF THE BLINDER-OAXACA DECOMPOSITION

    Oct 1, 2009, 00:00

  • CS12 IMPACTO EPIDEMIOLN DE LA VACUNA DE HEPATITIS A EN COLOMBIA

    Oct 1, 2009, 00:00

  • PCN112 COST MINIMIZATION ANALYSIS FOR STAPLED VERSUS HANDSEWN SURGERY TECHNIQUES FOR ANASTOMOSES IN SURGICAL TREATMENT FOR COLON CANCER, UNDER BRAZILIAN PRIVATE PAYER PERSPECTIVE

    Oct 1, 2009, 00:00

  • PIN35 CLINICAL AND ECONOMIC BENEFITS OF NATIONAL IMMUNIZATION WITH THE 13-VALENT COMPARED TO 7- AND 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINES IN GREECE

    Oct 1, 2009, 00:00

  • AC2 SUCCESS FACTORS IMPROVING PATIENT COMPLIANCE BEHAVIOUR-EMPIRICAL FINDINGS FROM EUROPE

    Oct 1, 2009, 00:00

  • PMC6 THE NATURE AND SCALE OF INADEQUATE REPORTING OF CONTINUOUS OUTCOMES FROM FOUR SYSTEMATIC REVIEWS

    Oct 1, 2009, 00:00

  • VA2 A HEALTH ECONOMIC EVALUATION OF A NEW HERPES ZOSTER (HZ) VACCINE FOR THE PREVENTION OF HZ AND POST-HERPETIC NEURALGIA (PHN) IN BELGIUM

    Oct 1, 2009, 00:00

  • PCV11 COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN FOR THROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT OR TOTAL KNEE REPLACEMENT IN COLOMBIA

    Oct 1, 2009, 00:00

  • PCV135 HEALTH STATUS IN AN ARGENTINIAN POPULATION SURVEY - RESULTS FROM THE NATIONAL RISK FACTOR SURVEY

    Oct 1, 2009, 00:00

  • PSS5 RESTOR VERSUS ACRILISA - ND-YAG LASER INCIDENCE RATE COMPARISON 18 MONTHS AFTER SURGERY

    Oct 1, 2009, 00:00

  • PP2 PATIENT PREFERENCES FOR BENEFIT-RISK TRADEOFFS AMONG POST-TRANSPLANT OUTCOMES IN END-STAGE RENAL DISEASE

    Oct 1, 2009, 00:00

  • PMC8 USING ATLAS.TI AS A TOOL TO EXTRACT AND SYNTHESIZE DATA OBTAINED IN LITERATURE REVIEWING

    Oct 1, 2009, 00:00

  • PIH33 DRUG USE BEFORE AND DURING PREGNANCY IN REPUBLIC OF SERBIA

    Oct 1, 2009, 00:00

  • PCN8 EVALUACI, COLOMBIA

    Oct 1, 2009, 00:00

  • PMS2 SAFETY OF LEFLUNOMIDE, METHOTREXATE AND SULFASALAZINE- ANALYSIS OF DATA FROM WHO PROGRAMME FOR INTERNATIONAL DRUG MONITORING

    Oct 1, 2009, 00:00

  • PMH7 EFFICACY OF ANTIPSYCHOTICS IN THE PREVENTION OF SCHIZOPHRENIA RELAPSE- A SYSTEMATIC REVIEW OF DOUBLE BLIND RANDOMISED CONTROLLED TRIALS

    Oct 1, 2009, 00:00

  • PCN77 COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS VS. SUNITINIB MALATE IN POOR PROGNOSIS METASTATIC RENAL CELL CARCINOMA (MRCC) IN PORTUGAL

    Oct 1, 2009, 00:00

  • PCV21 SELF-REPORTED GENERAL HEALTH WAS THE MOST INFLUENTIAL VARIABLE OF EQ-5D SOCIAL PREFERENCES SCORES IN A GENERAL POPULATION SURVEY IN ARGENTINA, AND ITS INFLUENCE DIFFERED ACCORDING TO GENDER, AGE AND INCOME STATUS

    Oct 1, 2009, 00:00

  • PHP69 DOES THE PROCEDURE MATTER? DIFFERENCES IN THE FUNDING OF DRUGS AND MEDICAL SERVICES IN AUSTRALIA

    Oct 1, 2009, 00:00

  • PIN10 A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH NEUTROPENIA IN SPAIN

    Oct 1, 2009, 00:00

  • PCN138 INFORMATION NEEDS- A STUDY ABOUT ONCOLOGICAL PATIENTS IN THE ITALIAN CONTEXT

    Oct 1, 2009, 00:00

  • PMC1 CORRECTING AN UNDERESTIMATE OF INCREMENTAL COST EFFECTIVENESS RATIO CONSIDERING STATISTICAL ERRORS AND PROBABILITY OF TRUTH

    Oct 1, 2009, 00:00

  • PCASE1 AMPLIANICAS-FMUSP- DESAFIOS E OPORTUNIDADES

    Oct 1, 2009, 00:00

  • PRS5 PRIMARY CARE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS FROM GENERAL PRACTICE DATABASE

    Oct 1, 2009, 00:00

  • PCV20 METABOLIC SYNDROME PATIENT COMPLIANCE WITH DRUG AND NON-DRUG TREATMENT

    Oct 1, 2009, 00:00

  • MO12 COMPARISON OF THREE META-MODELS FOR UNCERTAINTY ANALYSIS

    Oct 1, 2009, 00:00

  • PMS22 A COST-OF-ILLNESS STUDY OF PSORIATIC ARTHRITIS IN SPAIN

    Oct 1, 2009, 00:00

  • PMH14 ALZHEIMERS DISEASE- A PHARMACOEPIDEMIOLOGICAL STUDY

    Oct 1, 2009, 00:00

  • PDB14 THE BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN IN TYPE 2 DIABETES IN POLAND

    Oct 1, 2009, 00:00

  • PHP95 MEDICAL FOODS AND FOODS FOR SPECIAL MEDICAL PURPOSES

    Oct 1, 2009, 00:00

  • PMH12 COMPARISON OF POLYPHARMACY VS MONOTHERAPY ON OCCURRENCE OF RELAPSE IN SCHIZOPHRENIC PATIENTS - ADVANTAGE OF PROPENSITY SCORING ADJUSTMENT

    Oct 1, 2009, 00:00

  • PDB18 COST OFFSETS ASSOCIATED WITH USE OF EXENATIDE COMPARED TO GLARGINE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

    Oct 1, 2009, 00:00

  • PND30 MEDICATION ADHERENCE WITH DISEASE MODIFYING TREATMENTS FOR MULTIPLE SCLEROSIS- FINDINGS FROM A US NATIONAL DATABASE OF EMPLOYEES

    Oct 1, 2009, 00:00

  • PCV109 COST EFFECTIVENESS OF STATIN THERAPY IN SOUTH KOREA

    Oct 1, 2009, 00:00

  • PCV61 COST OF EXERCISE TRAINING AND ITS IMPACT ON MEDICAL RESOURCE USE AND COSTS- RESULTS OF HF-ACTION TRIAL

    Oct 1, 2009, 00:00

  • PCN4 ERYTHROPOIESIS STIMULATING AGENTS (ESA) FOR THE TREATMENT OF CHEMOTHERAPY INDUCED ANEMIA IN PATIENTS WITH HEMOGLOBIN LEVELS (HB) 11G/DL-A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2009, 00:00

  • CS18 ECONOMIC EVALUATION OF BARIATRIC SURGERY AS TREATMENT FOR OBESITY AND ASSOCIATED COMORBIDITIES-ESTIMATION BY DISCRETE EVENT SIMULATION

    Oct 1, 2009, 00:00

  • PMS83 COMPARISON OF A GENERIC UTILITY MEASURE (EQ-5D) AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS

    Oct 1, 2009, 00:00

  • PCV16 COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PCASE3 GESTDE

    Oct 1, 2009, 00:00

  • PCN117 COST-UTILITY MODEL TO EVALUATE ADJUVANT CHEMOTHERAPY FOR EARLY BREAST CANCER IN THE USA

    Oct 1, 2009, 00:00

  • PDB23 PREDICTING COST-EFFECTIVENESS OF A DIABETES HEALTH CARE PROGRAM IN BELGIUM AS A POLICY MANAGEMENT TOOL

    Oct 1, 2009, 00:00

  • PCV19 REVISTICA DE ESTUDOS DE CUSTO-EFETIVIDADE DA ROSUVASTATINA VS. ATORVASTATINA

    Oct 1, 2009, 00:00

  • PCV148 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HYPERCHOLESTEROLEMIA

    Oct 1, 2009, 00:00

  • PCV86 COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION IN HIGH-RISK PATIENTS WITH SYMPTOMATIC AORTIC VALVE STENOSIS IN FRANCE

    Oct 1, 2009, 00:00

  • PMH53 PATTERNS OF HEALTH CARE RESOURCE UTILIZATION IN JAPANESE PSYCHIATRIC OUTPATIENTS- RESULTS FROM THE ONE-DAY SURVEY CONDUCTED BY THE JAPANESE ASSOCIATION OF NEUROPSYCHIATRIC CLINICS

    Oct 1, 2009, 00:00

  • MC3 PREDICCIN- PRUEBA DE CONCEPTO

    Oct 1, 2009, 00:00

  • PIN62 COST-EFFECTIVENESS OF TARGETED SCREENING FOR HEPATITIS C IN THE NETHERLANDS

    Oct 1, 2009, 00:00

  • PIN69 A PATIENT SATISFACTION QUESTIONNAIRE FOR ASSESSING PHARMACEUTICAL CARE SERVICES IN NIGERIAN HIV CLINICS

    Oct 1, 2009, 00:00

  • PRS8 OPTIMA MODEL-BASED COST-UTILITY ANALYSIS OF FIXED COMBINATIONS SALMETEROL/FLUTICASONE VS. BUDESONIDE/FORMOTEROL IN TREATMENT OF ASTHMA IN RUSSIA

    Oct 1, 2009, 00:00

  • PIH17 ECONOMIC EVALUATION OF THE TRANSDERMAL CONTRACEPTIVE PATCH EVRA IN MEXICO- THE POPULAR HEALTH CARE SYSTEM PERSPECTIVE

    Oct 1, 2009, 00:00

  • PSY12 ECONOMIC AND CLINICAL EFFICACY BENEFITS OF THE USE OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE

    Oct 1, 2009, 00:00

  • PMH6 COSTO-EFECTIVIDAD DE OCHO MEDICAMENTOS ANTIPSICTICOS EN COLOMBIA

    Oct 1, 2009, 00:00

  • PMH16 PREDICTIVE FACTORS FOR HOSPITALIZATION IN FRENCH SCHIZOPHRENIC PATIENTS

    Oct 1, 2009, 00:00

  • PCV129 METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE WITH COMMON TREATMENTS

    Oct 1, 2009, 00:00

  • PCN156 EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC CHANGE ON THE GERMAN ONCOLOGY MARKET

    Oct 1, 2009, 00:00

  • PCN108 PHARMAECONOMIC EVALUATION OF THE USE OF PROLONGED LIBERATION HIDROMORFONE IN THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN FOR CANCER AT AN INSTITUTIONAL LEVEL IN MEXICO

    Oct 1, 2009, 00:00

  • PSY1 SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY OF PHARMACOTHERAPIES USED IN CHRONIC LOW BACK PAIN

    Oct 1, 2009, 00:00

  • PMC13 INDIRECT COST OF ILLNESS IN POLISH ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES

    Oct 1, 2009, 00:00

  • PG11 A RECORD-LINKAGE STUDY OF ADVERSE UPPER GASTRO-INTESTINAL EVENTS WITH NSAIDS IN A UK POPULATION UTILISING DIFFERENT EPIDEMIOLOGICAL DESIGNS TO MINIMISE CONFOUNDING

    Oct 1, 2009, 00:00

  • PCV96 COST-EFFECTIVENESS ANALYSIS OF IVABRADINE IN CHRONIC STABLE ANGINA PATIENTS IN A FINNISH SETTING

    Oct 1, 2009, 00:00

  • PHP80 CLINICAL EFFECTIVENESS OF PORTABLE ULTRASOUND IN SMALL EMERGENCY DEPARTMENTS- A SYSTEMATIC REVIEW

    Oct 1, 2009, 00:00

  • PCN16 EVALUATION OF THE EFFICACY OF THE POPULATION-BASED CERVICAL CANCER SCREENING IN HUNGARY

    Oct 1, 2009, 00:00

  • PCV51 THE POTENTIAL ECONOMIC IMPACT OF RECONFIGURING TIA CARE IN ITALY

    Oct 1, 2009, 00:00

  • PDB15 COST OF AN EPISODE OF DIABETIC FOOT ULCER IN SPAIN

    Oct 1, 2009, 00:00

  • PDB9 IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE

    Oct 1, 2009, 00:00

  • PMH7 HEALTH CARE RESOURCE UTILIZATION IN THE TREATMENT OF DEPRESSION IN MEXICO

    Oct 1, 2009, 00:00

  • PIN22 QU FACTORES DETERMINAN LOS PRECIOS INTERNACIONALES DE LOS MEDICAMENTOS ANTIRETROVIRALES?

    Oct 1, 2009, 00:00

  • PMS3 PROPORTION OF PATIENTS WITH OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN PERFORMING A BONE MINERAL DENSITY DIAGNOSIS MEASUREMENT- THE PRESAGE STUDY

    Oct 1, 2009, 00:00

  • PCN20 REAL LIFE TREATMENT DURATION OF SORAFENIB OR SUNITINIB IN FIRST LINE METASTATIC RENAL CELL CARCINOMA PATIENTS- A COMPARATIVE ANALYSIS

    Oct 1, 2009, 00:00

  • PDB16 GLYCEMIC CONTROL IN THE INPATIENT SETTING- INSULIN ASPART COMPARED TO HUMAN BOLUS INSULIN

    Oct 1, 2009, 00:00

  • PCV153 MARYLAND MENS CARDIOVASCULAR PROMOTION-MVP

    Oct 1, 2009, 00:00

  • PSS2 COMPARISON OF OUTCOMES FOR MULTIFOCAL INTRA-OCULAR LENSES (MIOLS)- A META-ANALYSIS

    Oct 1, 2009, 00:00

  • PSY19 DIRECT AND INDIRECT COSTS FOR PATIENTS WITH OPIOID INDUCED CONSTIPATION (OIC) AFTER TREATMENT WITH STRONG OPIOIDS IN SWEDEN

    Oct 1, 2009, 00:00

  • PIN38 COST-EFFECTIVENESS ANALYSIS OF PALIVIZUMAB IN THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN KOREAN CHILDREN WITH CONGENITAL HEART DISEASE

    Oct 1, 2009, 00:00

  • PMC71 THE EVOLVING HEALTH ECONOMICS EVALUATION PARADIGM AND THE ROLE OF THE QALY

    Oct 1, 2009, 00:00

  • PIN32 COST EFFECTIVENESS OF UNIVERSAL ROTAVIRUS VACCINATION IN IRELAND- A PRELIMINARY ANALYSIS

    Oct 1, 2009, 00:00

  • PR4 LINEAR SCORING RULES FOR PATIENT REPORTED OUTCOMES AND PATIENT PREFERENCES

    Oct 1, 2009, 00:00

  • PCV108 COST EFFECTIVENESS OF MPLANTABLE LOOP RECORDERS (ILRS) FOR UNEXPLAINED SYNCOPE DIAGNOSTICS IN FRANCE

    Oct 1, 2009, 00:00

  • PMH25 CLINICAL AND ECONOMIC CONSEQUENCES OF MEDICATION NONADHERENCE IN THE TREATMENT OF PATIENTS WITH A MANIC/ MIXED EPISODE OF BIPOLAR DISORDER- RESULTS FROM THE EUROPEAN MANIA IN BIPOLAR LONGITUDINAL EVALUATION OF MEDICATION (EMBLEM) STUD ...

    Oct 1, 2009, 00:00

  • PND16 ECONOMIC IMPACT OF GENERIC ENTRY OF TOPIRAMATE IN GERMANY- CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF GERMANY

    Oct 1, 2009, 00:00

  • PSY1 FIRST BRAZILIAN REGISTRY OF BIOLOGICAL TREATMENT IN PSORIASIS PATIENTS- PRELIMINARY CONCEPT AND RESULTS

    Oct 1, 2009, 00:00

  • PMC19 EVALUATING AN ONLINE INCREMENTAL COST-EFFECTIVENESS CALCULATOR STRUCTURED AS A DECISION ANALYTIC TREE THAT IMPLEMENTS MONTE CARLO SIMULATIONS OF KEY VARIABLES

    Oct 1, 2009, 00:00

  • PIH16 ECONOMIC EVALUATION OF TWO ALTERNATIVE TREATMENTS FOR OVARIAN STIMULATION IN ASSISTED REPRODUCTION

    Oct 1, 2009, 00:00

  • PSS23 COST-EFFECTIVENESS ANALYSIS OF IMIQUIMOD VERSUS NO TREATMENT IN ACTINIC KERATOSES

    Oct 1, 2009, 00:00

  • PIH5 AVALIAO E HISTERECTOMIA

    Oct 1, 2009, 00:00

  • PCN19 A LITERATURE REVIEW ON THE CLINICAL AND ECONOMIC OUTCOMES ATTRIBUTABLE TO FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML) WITH IMATINIB MESYLATE AND BONE MARROW TRANSPLANTATION (BMT)

    Oct 1, 2009, 00:00

  • PCN144 PATTERNS OF EMPLOYMENT AFTER CANCER- RESULTS OF A LONGITUDINAL STUDY

    Oct 1, 2009, 00:00

  • PCN147 FIELD TESTING OF A MULTICRITERIA DECISION ANALYSES (MCDA) FRAMEWORK FOR COVERAGE OF A DIAGNOSTIC TEST FOR CERVICAL CANCER IN SOUTH AFRICA

    Oct 1, 2009, 00:00

  • PMC67 LINGUISTIC ADAPTATION OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) INTO ENGLISH

    Oct 1, 2009, 00:00

  • PSY13 REIMBURSEMENT OF FOODS FOR SPECIAL MEDICAL PURPOSES PRODUCTS FOR PHENYLKETONURIA IN POLAND- A BUDGET IMPACT ANALYSIS

    Oct 1, 2009, 00:00

  • MH1 A DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE DISORDER-COST-EFFECTIVENESS ANALYSIS OF AGOMELATINE

    Oct 1, 2009, 00:00

  • PCN44 TREATMENT COSTS OF GRADE 3/4 ADVERSE EVENTS RELATED TO FIRST-LINE THERAPY WITH BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

    Oct 1, 2009, 00:00

  • PSY57 REIMBURSEMENT OF INNOVATIVE DRUGS IN SLOVAKIA-PHARMACOECONOMICS OF USTEKINUMAB IN PSORIASIS

    Oct 1, 2009, 00:00

  • HP1 CONHECIMENTO DA POPULASTICO

    Oct 1, 2009, 00:00

  • HP5 PROFILE OF HTA USERS AND APPLICABILITY OF HTA REPORTS TO INFORM DECISIONS IN LATIN-AMERICA

    Oct 1, 2009, 00:00

  • PCN140 IMPACT OF TUMOR RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VELCADE/MELPHALAN/PREDNISONE (V-MP)- RESULTS FROM THE VISTA TRIAL

    Oct 1, 2009, 00:00

  • PHP92 COMPARISON OF THE TIME TO PREPARE CONTRAST MEDIA INJECTION IN CT SCAN EXAM WITH PREFILLED SYRINGES AND BOTTLES IN 7 EUROPEAN COUNTRIES

    Oct 1, 2009, 00:00

  • PRS4 INDIRECT COMPARISON OF EFFICACY AND SAFETY OF FLUTICASONE AND BUDESONIDE IN THE TREATEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Oct 1, 2009, 00:00

  • PCV7 IMPACTO ECONACA (IC), SOB A PERSPECTIVA DO SISTEMA UNICO DE SAUDE (SUS), NO BRASIL

    Oct 1, 2009, 00:00

  • PMC3 ESTADO DEL ARTE DE LA EVALUACITICA DE LA LITERATURA

    Oct 1, 2009, 00:00

  • PCASE2 REMUNERAO BASEADA EM PERFORMANCE- O QUE EXISTE DE DIFERENTE DA CONSULTA BONIFICADA UTILIZADA EM ALGUMAS UNIMEDS

    Oct 1, 2009, 00:00

  • PRS13 THE CZECH BURDEN STUDY- SUBGROUP ANALYSIS (BURDEN AND QUALITY OF LIFE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION)

    Oct 1, 2009, 00:00

  • PDB53 COMORBID DEPRESSION IN PATIENTS DIAGNOSED WITH TYPE 2 DIABETES (T2DM)- EFFECTS ON WORK PRODUCTIVITY

    Oct 1, 2009, 00:00

  • PMS66 GRAND- THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES

    Oct 1, 2009, 00:00

  • PIN29 COST OF DIABETIC FOOT INFECTIONS DUE TO MRSA- AN ECONOMIC ANALYSIS OF DATA FROM PATIENTS TREATED WITH LINEZOLID IN SPAIN

    Oct 1, 2009, 00:00

  • PHP4 MUDANO A CAMINHO?

    Oct 1, 2009, 00:00

  • PG120 EFFECT OF SUBCUTANEOUS (SC) METHYLNALTREXONE ON PATIENT REPORTED CONSTIPATION SPECIFIC QUALITY OF LIFE IN A RANDOMIZED DOUBLE-BLIND CLINICAL TRIAL

    Oct 1, 2009, 00:00

  • PCV77 HEALTH CARE COSTS AND RESOURCE UTILIZATION FOR ACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT DIABETES MELLITUS

    Oct 1, 2009, 00:00

  • PSY44 LINGUISTIC VALIDATION OF HAEMOPHILIA-SPECIFIC PATIENT-RATED OUTCOMES (HAEMO-QOL, HAEM-A-QOL, HEMO-SAT) IN UP TO 32 LANGUAGES

    Oct 1, 2009, 00:00

  • PSS26 EXPECTED VALUE OF PARTIAL PERFECT INFORMATION IN A MARKOV MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE TYPE PSORIASIS

    Oct 1, 2009, 00:00

  • PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER- CANADIAN PERSPECTIVE

    Oct 1, 2009, 00:00

  • PDB25 A PATIENT-LEVEL SIMULATION MODEL FOR ECONOMIC EVALUATION OF CINACALCET IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN ITALY

    Oct 1, 2009, 00:00

  • PCV117 COST-UTILITY OF BOSENTAN IN THE FIRST-LINE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN FINLAND-A DISCRETE EVENT SIMULATION MODELLING

    Oct 1, 2009, 00:00

  • PIH32 WOMENS PREFERENCES FOR OVARIAN STIMULATING HORMONES IN THE TREATMENT OF INFERTILITY

    Oct 1, 2009, 00:00

  • PHP10 GERENCIAMENTO DE DOENDE?

    Oct 1, 2009, 00:00

  • PCV9 AVALIAO PARA PACIENTES AMBULATORIAIS MEDICADOS COM ANTI-HIPERTENSIVOS

    Oct 1, 2009, 00:00

  • PMS19 BUDGET IMPACT ANALYSIS OF TOCILIZUMAB UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Oct 1, 2009, 00:00

  • PGI4 ESTUDO FARMAECONO DO OMEPRAZOL EM UTI

    Oct 1, 2009, 00:00

  • PSY14 COST-EFFECTIVENESS AND BUDGET IMPACT OF LOW DOSE 7-DAY BUPRENORPHINE PATCH FOR MODERATE TO SEVERE OSTEOARTHRITIS PAIN IN THE CONTEXT OF KOREA NATIONAL HEALTH INSURANCE

    Oct 1, 2009, 00:00

  • PDB13 MEDICATION PATTERN AND RISK OF STROKE AMONG TYPE II DIABETES MELLITUS IN TAIWAN-A POPULATION-BASED STUDY

    Oct 1, 2009, 00:00

  • PCN73 COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY

    Oct 1, 2009, 00:00

  • PSS3 A COMPREHENSIVE SYSTEMATIC REVIEW OF THE PSYCHOMETRIC PROPERTIES OF VFQ-25 IN GLAUCOMA

    Oct 1, 2009, 00:00

  • PRS44 CLINICO-PHARMACOLOGICAL PRESENTATION AND THE OUTCOME OF QUALITY OF LIFE OF PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

    Oct 1, 2009, 00:00

  • PMS73 CONTENT VALIDITY OF THE FIBROMYALGIA SYNDROME BURDEN ASSESSMENT (FMBA)

    Oct 1, 2009, 00:00
  • «
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137 (current)
  • 138
  • 139
  • 140
  • »